Background Organ transplant recipients (OTRs) have a highly increased risk of cutaneous squamous cell carcinomas (SCCs). Sensation of pain in cutaneous tumours is a powerful patient-reported warning signal for invasive SCCs in OTRs. Objectives To investigate the impact of painful vs. painless skin lesions and SCC vs. other skin lesions on the overall mortality risk in OTRs. Methods We followed 410 OTRs from 10 different centres across Europe and North America between 2008 and 2015. These patients had been enrolled in an earlier study to define clinically meaningful patient-reported warning signals predicting the presence of SCC, and had been included if they had a lesion requiring histological diagnosis. Cumulative incidences of overall mortality were calculated using Kaplan-Meier survival analysis, and risk factors were analysed with Cox proportional hazard analysis. Results There was an increased overall mortality risk in OTRs who reported painful vs. painless skin lesions, with a hazard ratio (HR) of 1Á6 [95% confidence interval (CI) 0Á97-2Á7], adjusted for age, sex and other relevant factors. There was also an increased overall mortality risk in OTRs diagnosed with SCC compared with other skin lesions, with an adjusted HR of 1Á7 (95% CI 1Á0-2Á8). Mortality due to internal malignancies and systemic infections appeared to prevail in OTRs with SCC. Conclusions We suggest that OTRs have an increased overall mortality risk if they develop painful skin lesions or are diagnosed with cutaneous SCC.
Summary
Background Organ transplant recipients (OTRs) have a highly increased risk of cutaneous squamous cell carcinomas (SCCs). Sensation of pain in cutaneous tumours is a powerful patient-reported warning signal for invasive SCCs in OTRs. Objectives To investigate the impact of painful vs. painless skin lesions and SCC vs. other skin lesions on the overall mortality risk in OTRs. Methods We followed 410 OTRs from 10 different centres across Europe and North America between 2008 and 2015. These patients had been enrolled in an earlier study to define clinically meaningful patient-reported warning signals predicting the presence of SCC, and had been included if they had a lesion requiring histological diagnosis. Cumulative incidences of overall mortality were calculated using Kaplan-Meier survival analysis, and risk factors were analysed with Cox proportional hazard analysis. Results There was an increased overall mortality risk in OTRs who reported painful vs. painless skin lesions, with a hazard ratio (HR) of 1Á6 [95% confidence interval (CI) 0Á97-2Á7], adjusted for age, sex and other relevant factors. There was also an increased overall mortality risk in OTRs diagnosed with SCC compared with other skin lesions, with an adjusted HR of 1Á7 (95% CI 1Á0-2Á8). Mortality due to internal malignancies and systemic infections appeared to prevail in OTRs with SCC. Conclusions We suggest that OTRs have an increased overall mortality risk if they develop painful skin lesions or are diagnosed with cutaneous SCC.
• The question is whether painful lesions and the development of SCCs can predict mortality risk in OTRs.
What does this study add?
• OTRs have an increased overall mortality risk if they develop painful skin lesions or are diagnosed with SCCs.
• This finding highlights the need for close and long-term follow-up of OTRs who present with SCCs or painful skin lesions in view of the higher overall mortality risk observed in these patients.
It has been well documented that organ transplant recipients (OTRs) have a highly increased risk of cutaneous squamous cell carcinomas (SCCs) compared with the general immunocompetent population, with reported increased risks of up to 50-to 100-fold. [1] [2] [3] In a previous study conducted by Skin
Care in Organ Transplant Patients Europe (SCOPE) and the International Transplant Skin Cancer Collaborative (ITSCC) we reported that sensation of pain in cutaneous tumours is a powerful patient-reported warning signal for invasive SCC in OTRs. 4 Therefore pain has been identified as a key feature of SCC in OTRs. 4, 5 This important symptom helps to empower patients to seek treatment earlier.
Other skin conditions such as basal cell carcinoma (BCC) can present with pain as well, 5 but we could not confirm this in the SCOPE-ITSCC PAIN study. 4 Pain in general has also been reported to be associated with an increased risk of mortality, although the exact relationship is unclear and there is a paucity of published data to date. [6] [7] [8] Earlier studies showed that OTRs with SCCs have an increased risk of mortality from both malignancy and other causes. [9] [10] [11] Increased overall mortality after SCC may not be explained by the occurrence of intervening cancers alone, but perhaps reflects a more general predisposition to life-threatening illnesses.
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In the current study we intended to study the fate of OTRs who presented with a painful vs. a painless skin lesion, and with SCC vs. other skin lesions, with regard to: (i) the development of subsequent SCC and/or BCC and (ii) their risk of overall mortality. Improving our understanding of the fate of painful skin lesions and the burden of SCC in OTRs is important, as these lesions can be found in a significant proportion of OTRs and increase with duration after transplantation.
Patients and methods
The original SCOPE-ITSCC PAIN study was performed between July 2008 and February 2011 in 10 centres dedicated to surveillance of OTRs with skin problems in Europe and the U.S.A. 4 This investigator-sponsored study was designed by the principal investigators and emerged from a joint initiative between SCOPE (http://www.scopenetwork.org/) and the ITSCC (http://www.itscc.org/). Each site's independent ethics committee or institutional review board approved the protocol and participants gave informed consent in accordance with the Declaration of Helsinki. OTRs could be included if they had a lesion requiring a histological diagnosis. Inclusion did not depend on past clinical history. The study was designed to define clinically meaningful patient-reported warning signals predicting the presence of SCC. Painful lesions vs. painless lesions appeared to be the most powerful patient-reported warning signal for invasive SCC in OTRs.
The questions in the original study covered different aspects of pain: spontaneous pain (without touch or palpation); tenderness by touching or palpation (no spontaneous pain); intensity of pain on a visual analogue scale from zero to 10 where zero denotes no pain and 10 strongest pain; pain disturbing sleep as well as itching; and bleeding of the lesion. For the current study, spontaneous pain and tenderness by touching or palpation were combined as painful lesions and compared with painless lesions. In the original study, multiple biopsies could be taken during the first visit and additional biopsies could be taken during follow-up visits. This resulted in the inclusion of 410 patients with a total of 812 skin biopsies.
Data collection
In the current study, further clinical data were collected in the period between 2007 and 2015 for patients enrolled in the initial SCOPE-ITSCC PAIN study cohort. These additional data consisted of dates of subsequent biopsies, body location and histological diagnosis (SCC/KA, BCC, Bowen disease or other skin tumours). Total numbers of tumours with different histological subtypes for each patient were also captured. The occurrences of locally aggressive SCCs, metastasis and death were recorded. Locally aggressive SCCs were defined as SCCs that were deeply invasive into the subcutaneous tissue or muscle and/or that locally recurred despite tumour-free excision margins at primary excision. Data on the cause of death were collected from the medical chart or the electronic system of the hospital.
Statistical methods and analyses
In this cohort study, included OTRs with painful skin lesions were compared with OTRs with painless lesions, and OTRs with diagnoses of SCC/keratoacanthoma (KA) were compared with those with other histological diagnoses in relation to the end points of subsequent skin cancer, metastasis and/or death.
P-values for categorical data were calculated using Pearson's two-sided χ 2 -test and for continuous data using analysis of variance. Survival probabilities were estimated using the KaplanMeier method. Crude curves were used to depict survival in the different subgroups. We used Cox proportional hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) associated with mortality for painful vs. painless skin lesions and SCC/KA vs. other skin lesions. The primary outcome measures were subsequent SCC/KA, BCC, metastasis and death. The starting date was the date of the first biopsy after initiation of the original SCOPE-ITSCC PAIN study, and the end date was the end of follow-up or date of death of the patient. HRs were adjusted for age, sex, time since transplant (time between transplant and date of first biopsy after initiation of the original SCOPE-ITSCC PAIN study), number of SCCs before the start of the study and, in the case of painful skin lesions, HR was additionally adjusted for a histological diagnosis of SCC/ KA, because these factors potentially confound the associations tested. The proportional hazard assumption was tested by introducing into the model an interaction term consisting of time and the group variable (i.e. SCC and/or KA vs. no SCC and/or KA). The hazard was assumed to be proportional if the interaction term was nonsignificant (P > 0Á05). In all analyses the hazard was proportional. SCC and KA are often considered to be part of the same skin malignancy spectrum and are frequently treated similarly. Therefore the histological diagnoses were grouped into invasive cutaneous SCC and/or KA and all other histological diagnoses. In sensitivity analyses SCCs were also analysed without KA, but this did not lead to significantly different outcomes.
When analysing the association between painful lesions and overall mortality risk we followed two strategies: firstly, we only considered the first 410 biopsies taken during the original study without taking any further biopsies into consideration; secondly, we considered all 812 skin biopsies taken during the original study and counted the number of painful lesions per patient.
When analysing the association between SCC/KA and overall mortality risk we considered the following categories of OTRs with SCC: (i) OTRs included in the original PAIN study with a biopsy of an SCC independent of past medical history of SCC ( For all analyses, we used the software package IBM SPSS Statistics, release 23Á0 2015 (IBM, Armonk, NY, U.S.A.).
Results
The original SCOPE-ITSCC PAIN study included 122 OTRs who presented with SCC/KA and 288 OTRs who presented with other skin lesions at the time of inclusion [ Table 1 ; Fig. S1 (see Supporting Information)]. Of the 122 OTRs with SCC/KA at inclusion, 88 (72Á1%) already had between one and 100 (mean 12, median 5) SCCs in their medical history and of the 288 OTRs who presented with other skin lesions at the time of inclusion, 91 (31Á6%) already had between one and 65 (mean 9, median 4) SCCs in their medical history [ Table 1 ; Fig. S1 (see Supporting Information)].
All 410 OTRs were included in the current cohort study. For three patients, data regarding SCC/KA during follow-up were not complete, and for an additional four patients we could not determine whether they were still alive or had died. Table 1 also shows patient characteristics stratified by the presence of SCC/KA at inclusion in the SCOPE-ITSCC PAIN study. A total of 91 (74Á6%) of the 122 patients with an SCC/ KA at inclusion in the SCOPE-ITSCC PAIN study subsequently developed one to 125 SCCs/KAs (mean 9, median 5). In total, 73 (80Á2%) of the additional 91 patients with a medical history of SCC before inclusion subsequently developed one to 64 SCCs/KAs (mean 7, median 3), and 50 (24Á9%) of the 201 patients without any SCC/KA developed their first SCC/ KA during the follow-up period (range 1-12, mean 3, median 2) [ Table 1 ; Fig. S1 (see Supporting Information)]. Figure 1 demonstrates the development of subsequent skin cancers following an earlier skin cancer. Presence of SCC/KA was predictive for the development of a subsequent SCC/KA (Fig. 1a) , and BCC predicted the development of a subsequent BCC (Fig. 1b) . On the other hand, presence of a BCC did not predict a new or subsequent SCC/KA (Fig. 1c) and SCC/KA did not predict a subsequent BCC (Fig. 1d) .
Painful skin lesions predicted an increased mortality risk (Fig. 2a) . As pain predicts SCC/KA we expected that painful SCC/KA would lead to the highest death rate but this was not the case: pain alone, SCC/KA alone and painful SCC/KA all led to the same increased mortality rate compared with painless lesions and non-SCC/KA lesions (Fig. 2b ). An OTR with a painful lesion had double the risk of overall mortality when the first biopsy per patient was analysed without taking the other biopsies into account ( Table 2 ). The majority of these painful lesions consisted of SCC, Bowen disease and actinic keratosis (Table 2 legend). After adjustment for age, sex, SCC/KA as the histological diagnosis, number of SCCs before inclusion in the study, and number of years after the transplantation there was still a 60% increased overall mortality risk in patients with a painful lesion (Table 3) . Taking all biopsies that were taken during the original study into account, we observed that the overall mortality risk increased even further where a patient had two or more painful lesions (Table 3) .
When analysing the impact of the development of SCC/KA on overall mortality risk two distinct clinical questions arise: (i) what is the prognosis regarding overall mortality risk of a patient who presents to a clinic with a first or new SCC/KA and (ii) what is the prognosis regarding overall mortality risk of a patient known to have an SCC/KA currently or in the past who develops an SCC/KA during the follow-up period? The analyses regarding the first question are depicted in Figure 3 and Table 4 , and regarding the second question in Table 5 .
A histological diagnosis of an SCC/KA, compared with a different histological diagnosis at the time of inclusion in the original SCOPE-ITSCC PAIN study, was associated with an increased overall mortality risk, with an HR of 1Á7 (95% CI 1Á0-2Á8), adjusted for age, sex, time since transplant and number of SCCs before the start of the study (Fig. 3 and Table 4 ). Examination of the association between SCC at any time before, at or in the follow-up period after the original SCOPE-ITSCC PAIN study showed a higher HR, which was 3Á9 (95% CI 1Á6-9Á4) after adjustment for the same factors ( Table 5 ). The mean number of SCCs in patients with SCC was 7Á1 in the OTRs who were still alive and 7Á8 in OTRs who had died (P = 0Á717). Other skin lesions consisted of 76 (26Á4%) basal cell carcinomas; 37 (12Á8%) Bowen disease; 34 (11Á8%) actinic keratosis; 19 (6Á6%) seborrheic keratoses; 14 (4Á9%) common warts; nine (3Á1%) hyperkeratotic papillomas; seven (2Á4%) other skin malignancies; one (0Á3%) infection; and 91 (31Á6%) miscellaneous diagnoses (mainly all kinds of naevi, dermatofibroma and epidermoid cysts).
Among the 260 patients who had developed one or more SCCs/KAs, there were nine patients with metastasis, of which five originated from an aggressive SCC. Three of the nine patients with metastasis were still alive at the end of the study. Five patients died of metastatic SCC and one patient died of bone marrow cancer. Among 10 patients with aggressive SCC (five of them also had metastatic disease), four were still alive at the end of the study. One patient died of aggressive SCC located on the face without metastasis, three died of metastatic SCC, one died of gastrointestinal malignancy and one died of pneumonia. Table 6 shows the various causes of death in OTRs who had painful lesions or no painful lesions, and in Table 7 causes of death are compared between OTRs with SCC/KA and those without SCC/KA. It is of interest that mortality from systemic infection appeared to predominate in patients with SCC/KA compared with those without SCC/KA; however, because of the small numbers statistical significance was not reached. Altogether six OTRs died of SCC, in five cases because of metastatic SCC and once case due to an aggressive SCC without metastasis.
Discussion
In our study, SCCs/KAs are frequently followed by new SCC/ KA, and similarly BCC increases the likelihood of development of subsequent BCC. This trend has been reported in earlier papers, and our study further validated these findings. 13, 14 Flohil et al. reported that patients with a BCC had a 17-fold increased risk of developing a subsequent BCC compared with the BCC risk in the general population, and SCC patients had a four-fold risk of developing a subsequent SCC compared with the general population. 15 This type-specific predilection may be a consequence of particular genetic susceptibilities; for example, individuals in the BCC-only group may carry mutations of genes in the Hedgehog pathway or sporadic variants of Patched or other germline mutations. 13 In addition, the pattern of previous sun exposure, that is continuous sun exposure for SCC and intermittent sun exposure for BCC, may be another explanatory factor. Adjusted for age at start of study and sex 1Á9 (1Á2-3Á2) 3Á1 (1Á7-5Á5) Adjusted for age, sex, SCC/KA as the histological diagnosis, number of SCCs before inclusion in the study, and number of years after the transplantation until inclusion in the study
HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; KA, keratoacanthoma.
We observed an increased overall mortality in OTRs with painful skin lesions that was independent of histological diagnosis. There was also a positive association between the number of painful lesions and overall mortality. Our previous SCOPE-ITSCC PAIN study had excluded a significant association between perineural invasion and pain in SCC/KA and had not revealed a local factor for the pain recorded in skin lesions. Smith et al. have reported in a systematic review that chronic pain in general increased mortality 7 and Feeny et al.
have also reported pain in general as a predictor for mortality; 16 however, the exact relationship is unclear. There is also a lack of published data on the relationship between acute pain and mortality. Potentially, skin lesions could be perceived as painful more often in people of lesser health with a lower threshold for perception of pain. Alternatively, in persons with lesser health, SCC could behave more aggressively along with local induction of pain by as yet unknown mediators. However, painful skin lesions might be used as a clinical indicator to inform clinicians on the poorer prognosis of this group of individuals, who might benefit from additional management, further investigation or more intensive follow-up. The occurrence of SCC/KA during the cohort study was analysed as a time-dependent variable. Our study shows that OTRs who are under regular surveillance in centres dedicated to managing OTR-related skin problems have a very high burden of SCC/KA. Our study also supports the finding that OTRs have an increased overall mortality risk if they are diagnosed with SCC/KA. The most prevalent causes were internal malignancies and severe systemic infections. However, the contribution of metastatic SCC to this increased mortality risk is limited, as only 10% of the mortality risk was attributable to metastatic SCC. Interestingly, part of the increased mortality risk compared with OTRs without SCC/KA could be attributed to severe systemic infections, which were observed more frequently in OTRs with a history of SCC/KA. We do not have an explanation for this observation, but reduced immunity may possibly be a factor leading to more SCC and at the same time an increased risk of severe systemic infections.
The strengths of our study include the large number of patients from multiple centres in Europe and North America. This is also the first paper to describe the mortality risk associated with painful skin lesions or SCC/KA. Limitations of this study include selection bias resulting from including OTRs predominantly in specialist OTR referral centres, and potential inaccuracies and missing information on cause of death in 25% of the study group, as well as possible confounding factors like past sun exposure, smoking and the presence of internal malignancies and/or cardiac disease before the diagnosis of cutaneous SCC.
In conclusion, OTRs have an increased overall mortality risk if they develop painful skin lesions independent of histological diagnoses or are diagnosed with SCC/KA. The development of SCC should warn the clinician that the patient may have an increased risk of internal malignancies and/or serious infections, with death as a possible end result. Our study highlights the need for close and long-term follow-up of OTRs who present with SCC or painful skin lesions, in view of the higher overall mortality risk observed in these patients.
